Table 1.
Baseline characteristics of patients who reached steroid-free remission
| CD [N = 66] | UC [N = 42] | Total [N = 108] | |
|---|---|---|---|
| Sex, female | 43 [65%] | 24 [57%] | 67 [62%] |
| Age group | |||
| 18–30 years | 15 [23%] | 10 [24%] | 25 [23%] |
| 30–50 years | 19 [29%] | 17 [40%] | 36 [34%] |
| 50–65 years | 24 [36%] | 10 [24%] | 34 [32%] |
| >65 years | 8 [12%] | 5 [12%] | 13 [12%] |
| Mean age at diagnosis, years | 39 [SD 15.1] | 36 [SD 15.1] | 38 [SD 15.1] |
| Mean age at baseline, years | 47 [SD 14.2] | 44 [SD 15.8] | 46 [SD 14.8] |
| Mean weight, kg | 78.0 [SD 17.2] | 84.2 [SD 16.7] | 80.0 [SD 17.2] |
| Mean BMI, kg/m2 | 26.2 [SD 6.2] | 27.6 [SD 6.2] | 26.8 [SD 6.2] |
| Mean IBD disease duration, years | 8.2 [SD 9.4] | 7.6 [SD 7.8] | 8.0 [SD 8.8] |
| Smoking | |||
| Current | 21 [32%] | 4 [10%] | 25 [23%] |
| Previous | 25 [38%] | 17 [41%] | 42 [39%] |
| Never | 20 [30%] | 21 [50%] | 41 [38%] |
| Alcohol consumption | |||
| None | 31 [47%] | 20 [48%] | 51 [47%] |
| 1–2 drinks per week | 19 [29%] | 9 [21%] | 28 [26%] |
| 3–5 drinks per week | 6 [9%] | 4 [10%] | 10 [9%] |
| 6–9 drinks per week | 4 [6%] | 4 [10%] | 8 [7%] |
| ≥10 drinks per week | 6 [9%] | 3 [7%] | 9 [8%] |
| Unknown | 0 [0%] | 2 [5%] | 2 [2%] |
| Montreal classification CD | |||
| Behaviour | |||
| Non-stricturing/non-penetrating [B1] | 43 [65%] | ||
| Stricturing [B2] | 19 [29%] | ||
| Penetrating [B3] | 2 [3%] | ||
| Peri-anal disease [+P] | 2 [3%] | ||
| Location | |||
| Ileum [L1] | 30 [46%] | ||
| Colon [L2] | 18 [27%] | ||
| Ileocolon [L3] | 16 [24%] | ||
| Upper GI [+L4] | 2 [3%] | ||
| Montreal classification UC | |||
| Extent | |||
| Proctitis [E1] | 5 [12%] | ||
| Left-sided [E2] | 23 [55%] | ||
| Pancolitis [E3] | 12 [29%] | ||
| Other | 2 [5%] | ||
| Severity | |||
| Remission [S0] | 15 [36%] | ||
| Mild [S1] | 11 [26%] | ||
| Moderate [S2] | 14 [33%] | ||
| Severe [S3] | 2 [5%] | ||
| Extra-intestinal manifestations | 12 [18%] | 5 [12%] | 17 [16%] |
| Prior thiopurine use | |||
| AZA | 29 [44%] | 21 [50%] | 50 [46%] |
| MP | 37 [56%] | 18 [43%] | 55 [51%] |
| Both AZA and MP | 0 [0%] | 3 [7%] | 3 [3%] |
| Other therapies in the year before inclusion | |||
| Steroids | 45 [68%] | 26 [62%] | 71 [66%] |
| 5-ASA | 15 [23%] | 31 [74%] | 46 [43%] |
| Methotrexate | 10 [15%] | 3 [7%] | 13 [12%] |
| Anti-TNF therapy | 14 [21%] | 5 [12%] | 19 [18%] |
CD: Crohn’s disease; UC: ulcerative colitis; IBD: inflammatory bowel disease; BMI: body mass index; GI, gastrointestinal; AZA: azathioprine; MP: mercaptopurine; 5-ASA: 5-aminosalicylic acid; TNF, tumour necrosis factor.